Actinium Pharmaceuticals to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference Mar 15, 2019
Actinium's Late Breaking Oral Presentation at 2019 TCT Meetings Reports New Data on Donor Chimerism Indicating Deep Engraftment in All Iomab-B Treated Patients in the Pivotal Phase 3 SIERRA Trial Feb 25, 2019
Actinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy Feb 21, 2019
Iomab-B One of Four Late Breaking Oral Presentations to be Presented at the 2019 Transplantation & Cellular Therapy Annual Meeting Feb 12, 2019
Actinium Provides Patent Portfolio Update for its Iomab-ACT Next-Generation CAR-T Lymphodepletion Program Feb 6, 2019
Actinium Initiates Second Dosing Cohort of Novel Combination Trial with Actimab-A and CLAG-M Salvage Regimen at Medical College of Wisconsin Feb 4, 2019
Actinium Pharmaceuticals to Host Key Opinion Leader Breakfast on Targeted Conditioning for Bone Marrow Transplant and CAR-T on February 7th Jan 29, 2019
Actinium Pharmaceuticals, Inc. to Present at Noble Capital Markets' 15th Annual Investor Conference Jan 25, 2019
